Ardsley Advisory Partners LP Abb Vie Inc. Transaction History

Ardsley Advisory Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $8.77 Million - $11.8 Million	-109,000 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$85.91 - $100.83 $10.4 Million - $12.3 Million	-121,500 Reduced 52.71%	109,000 $9.54 Million
Q2 2020 Aug 14, 2020	BUY	$73.37 - $98.18 $10.4 Million - $13.9 Million	141,500 Added 158.99%	230,500 $22.6 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $5.74 Million - $8.7 Million	89,000 New	89,000 $6.77 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $19.1 Million - $25.6 Million	-207,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $18.1 Million - $19.9 Million	202,500 Added 4050.0%	207,500 $20.1 Million
Q3 2017 Nov 14, 2017	SELL	$69.85 - $89.22 $174,625 - $223,050	-2,500 Reduced 33.33%	5,000 $444,000
Q2 2017 Sep 21, 2017	BUY	N/A	7,500	7,500 $544,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.